Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

165 questions in 15 reviews · Childhood Cancer

current versions

No studies 50 · 30.3%Ungraded 12 · 7.3%Very low 13 · 7.9%Low 69 · 41.8%Moderate 21 · 12.7%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Hyperfractionated radiotherapy vs conventional radiotherapy Progression‐free survival · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	no estimate extracted	NR	No studies
Hyperfractionated radiotherapy vs conventional radiotherapy Event‐free survival · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	HR 1.26 [0.83, 1.9]	1 study · 130 participants	Low
Hyperfractionated radiotherapy vs conventional radiotherapy Quality of life · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	no estimate extracted	NR	No studies
Hyperfractionated radiotherapy vs conventional radiotherapy Neurological response · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	no estimate extracted	NR	No studies
Hyperfractionated radiotherapy vs conventional radiotherapy Radiological response defined as the number of participants with a reduction in tumour size > 50% · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	RR 0.94 [0.54, 1.63]	1 study · 108 participants	Very low
Hyperfractionated radiotherapy vs conventional radiotherapy Toxicities · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	no estimate extracted	1 study · 112 participants	Very low
Hypofractionated radiotherapy vs conventional radiotherapy Overall survival · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	HR 1.03 [0.53, 2.01]	1 study · 71 participants	Moderate
Hypofractionated radiotherapy vs conventional radiotherapy Progression‐free survival · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane	HR 1.19 [0.63, 2.22]	1 study · 71 participants	Low
Rapid COJEC vs standard induction therapies Complete response · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	RR 0.99 [0.71, 1.38]	1 study · 170 participants	Low
Rapid COJEC vs standard induction therapies Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	no estimate extracted	1 study · 248 participants	Low
Rapid COJEC vs standard induction therapies Treatment‐related mortality · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	RR 1.21 [0.33, 4.39]	1 study · 234 participants	Low
Rapid COJEC vs standard induction therapies Overall survival · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	HR 0.83 [0.63, 1.1]	1 study · 262 participants	Low
Rapid COJEC vs standard induction therapies Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	no estimate extracted	NR	No studies
Rapid COJEC vs standard induction therapies Event‐free survival · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	HR 0.86 [0.65, 1.13]	1 study · 262 participants	Low
Rapid COJEC vs standard induction therapies Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate < 80 ml/min per body surface area of 1.73 m2), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included di... · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane	no estimate extracted	1 study · 57 participants	Low